Business · 14/06/1994Updated: 10/16/2026 · 1 min read
Correction to Notice of Determination of Regulatory Review Period for Purposes of Patent Extension for MycobutinTM
Summary
The Food and Drug Administration (FDA) is correcting a notice with mathematical errors regarding the regulatory review period for MycobutinTM (rifabutin) patent extension.
Original source language: Federal Register — Health and Human ServicesOpen original release →